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Treating advanced or recurrent melanoma remains a challenge. Cancer cells can
evade the immune system by blocking T-cell activation through overexpression
of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor
nivolumab blocks the inhibitory signal in T cells, thus overcoming the immune
resistance of cancer cells. Nivolumab has shown promising anticancer activity in
various cancers. We carried out a single-arm, open-label, multicenter, phase II
study to investigate the efficacy and safety of nivolumab in previously untreated
Japanese patients with advanced melanoma. Twenty-four patients with stage III/
IV or recurrent melanoma were enrolled and received i.v. nivolumab 3 mg/kg
every 2 weeks until disease progression or unacceptable toxicity. The primary
endpoint was overall response rate evaluated by an independent radiology
review committee. The independent radiology review committee-assessed overall
response rate was 34.8% (90% confidence interval, 20.8–51.9), and the overall
survival rate at 18 months was 56.5% (90% confidence interval, 38.0–71.4). Treat-
ment-related adverse events (AEs) of grade 3 or 4 only occurred in three patients
(12.5%). Two patients discontinued nivolumab because of AEs, but all AEs were
considered manageable by early diagnosis and appropriate treatment. Subgroup
analyses showed that nivolumab was clinically beneficial and tolerable regardless
of BRAF genotype, and that patients with treatment-related select AEs and with
vitiligo showed tendency for better survival. In conclusion, nivolumab showed
favorable efficacy and safety profiles in Japanese patients with advanced or
recurrent melanoma, with or without BRAF mutations. (Trial registration no.
JapicCTI-142533.)
A dvanced or recurrent melanoma is a challenging diseaseto treat. Dacarbazine was approved for use in the USA in
1975, since when it has been a standard therapy for advanced
melanoma; however, the efficacy of dacarbazine monotherapy
is unsatisfactory.(1,2) Melanoma is still associated with high
mortality, despite recent advancements in systemic therapy that
have improved the 10-year survival rate of patients with dis-
tant metastatic melanoma from <10% in 2001(3) to approxi-
mately 30% in 2009.(4) Effective, alternative therapy options
are therefore needed.
Immune checkpoint inhibitors have become a recent focus
of anticancer drug discovery. T-cell activation is tightly regu-
lated by the balance between positive and negative signals,
allowing T cells to recognize and respond to pathogens while
maintaining self-tolerance.(5) Checkpoint receptors are
expressed in T cells and induce inhibitory signals following
receptor binding. However, cancer cells overexpress immune
checkpoint ligands that inhibit T-cell activation, allowing the
cells to escape immune system attack,(6) whereas antagonists
of such receptors can increase antigen-specific T-cell immune
responses against tumor cells. Programmed death 1 and cyto-
toxic T-lymphocyte-associated antigen-4 are two of the most
intensively investigated target receptors in cancer immunother-
apy research. Unlike other antibody-based cancer therapies,
immune checkpoint inhibitors do not target tumor cells
directly, but rather modulate lymphocytes to enhance the
body’s own anticancer activities.
Nivolumab is a fully human mAb that inhibits the PD-1
checkpoint receptor. Expression of PD-1 on the T-cell surface
is upregulated following activation,(7) and the PD-1 pathway
negatively regulates effector T-cell activity following ligand
binding. Tumor cells usually overexpress the PD-1 ligands,
PD-L1 and PD-L2,(8,9) on the cell surface, thus acquiring
immune resistance. Indeed, the expression level of PD-L1 was
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shown to correlate with tumor growth in primary melano-
mas.(10) Blockade of PD-1 by nivolumab thus represents a
promising approach for enhancing the antimelanoma T cell
immune response, and thereby improving clinical end-
points.(11–13)
The present study investigated the efficacy and safety of
nivolumab in previously untreated Japanese patients with
advanced melanoma.
Material and Methods
Patients. This was a single-arm, open-label, multicenter,
phase II study to evaluate the efficacy and safety of nivolumab.
Eligible patients were at least 20 years old, with histopathologi-
cally confirmed, previously untreated malignant melanoma that
were unresectable stage III/IV or recurrent, an Eastern
Cooperative Oncology Group performance status score of 0 or
1,(14) a predicted survival of at least 3 months, and adequate
organ function. At least one tumor had to be measurable by
imaging, as defined using the RECIST guidelines (ver-
sion 1.1)(15) 14 days before enrollment. Enrollment of patients
with previous adjuvant therapies was allowed. Patients with the
following conditions were not enrolled: (i) history of hypersen-
sitivity to other antibody-based medications; (ii) remaining
influence of previous radiation or resection therapies; (iii)
chronic or recurrent autoimmune diseases; (iv) genotyping for
BRAF mutation not possible; (v) melanomas with primary
tumors in the esophagus or rectum; (vi) presence of double can-
cer, except completely resected cancers (basal cell carcinoma,
squamous cell carcinoma of stage 1, intraepithelial carcinoma,
intramucosal carcinoma, or superficial bladder cancer) or other
cancers without recurrence for 5 years; (vii) primary or meta-
static lesions in brain or meninges; or (viii) interstitial lung dis-
ease or pulmonary fibrosis. All patients provided tumor biopsy
specimens for gene analyses. The BRAF V600 mutation was
detected using real-time PCR (Cobas 4800 BRAF V600 Muta-
tion Test; Roche Diagnostics, Branford, CT, USA).
The study protocol was approved by the institutional review
board at each study site. The study was carried out in accor-
dance with the Declaration of Helsinki and the International
Conference on Harmonization Guideline for Good Clinical
Practice. Written informed consent was provided by all partici-
pants before the first treatment.
Interventions. The study consisted of three stages: screening,
intervention, and post-treatment follow-up. After the screening
stage, eligible patients were enrolled and received i.v. nivolu-
mab 3 mg/kg every 2 weeks in each 6-week cycle until pro-
gressive disease (PD) or unacceptable toxicity was observed.
Treatment was discontinued immediately when any of follow-
ing discontinuation criteria was met at any time during the
intervention stage: (i) complete response (CR) based on
RECIST guidelines, except patients with anticipated recurrence
assessed by investigators; (ii) PD based on RECIST guidelines,
and no further clinical benefit expected; (iii) clinical symptoms
indicating cancer progression; (iv) interstitial lung disease of
grade ≥2 regardless of the relationship to nivolumab; (v) AEs
of grade ≥3 of which the relationship to nivolumab was not
ruled out; or (vi) AEs (eye pain and visual acuity reduced) of
grade ≥2 that were not ruled out for their relationship to nivo-
lumab and not recovered after topical treatment. Tumors were
evaluated at the end of the 6-week regimen to determine if the
treatment should be continued. The follow-up stage began
when the treatment was discontinued or no new cycle was
started.
Assessment. Efficacy endpoints. Tumor images were
obtained using computed tomography or magnetic resonance
imaging at screening, and at the end of every 6-week treatment
cycle from the 1st to 9th cycles, and thereafter at the end of
every other 6-week cycle, and also at discontinuation of the
treatment and on the 28th day of the follow-up period. These
images were used to classify the overall response into four cat-
egories, based on the RECIST guidelines (version 1.1). The
primary endpoint was the ORR, defined as the proportion of
patients with CR or PR, assessed by an IRC. Secondary end-
points were the ORR assessed by investigators at each study
site, OS, PFS, duration of response, disease-control rate, and
change in tumor size.
Safety endpoints. Safety was assessed by recording AEs,
evaluated by vital signs, and the results of 12-lead electrocar-
diograms and clinical tests, collected at predefined time points.
Adverse events were graded using the Common Terminology
Criteria for Adverse Events version 4.0. The frequency of
treatment-related select AEs, defined as AEs with potential
immunological causes, was also recorded.
Statistical analysis. Demographic characteristics were
described as the summary statistics of the safety set, which
comprised patients who had received nivolumab at least once.
Efficacy endpoints were analyzed in the full-analysis set,
which comprised evaluable patients in the safety set who con-
tinued to fulfill the major eligibility criteria. The proportions
of patients and two-sided 90% CIs were calculated for the
ORR and disease-control rate. The OS and PFS were reported
as medians and two-sided 90% CIs, estimated using the
Kaplan–Meier method. The proportions of patients with CR,
PR, SD, PD, and not evaluable were calculated, and two-sided
90% CIs were calculated for CR, PR, and SD. The proportion
of patients who showed ORR for 12 months or longer was
estimated as the durable response rate using Kaplan–Meier
methods. Safety was analyzed in the safety set.
Patients were stratified into two groups based on BRAF
genotypes, and subgroup analyses were carried out to deter-
mine the nivolumab efficacy and safety endpoints in patients
with BRAF wild-type and mutant, respectively. In addition, we
undertook a posteriori subgroup analyses for several factors
that could influence the efficacy of nivolumab. Median OS and
PFS with two-sided 90% CIs were estimated for subgroups
using the Kaplan–Meier method and compared using unstrati-
fied log–rank tests and unstratified Cox proportional hazards
models.
The planned sample size was 20 patients. An earlier phase II
study in previously treated Japanese patients who received
nivolumab once every 3 weeks showed a response rate of
22.9%,(16) which were therefore set as the expected response
rate for the present study. The threshold response rate was set
as 6.0%, estimated based on the response rate to dacarbazine.
Using these estimates, the sample size was determined to 20
patients, with a statistical power of 80% ensured to detect the
response rate in a one-sided test with a 5.0% significance
level. The required sample size for patients with BRAF wild-
type was calculated as 14, using the same estimates with a sta-
tistical power of 70%, and the estimated sample size for
patients with BRAF mutant was six, so that at least one patient
would achieve a response with approximately 80% probability.
Results
Patients and treatment. A total of 24 patients from nine
study centers participated from May to October 2014, with a
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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data cut-off date of February 29, 2016. The demographic and
baseline characteristics are summarized in Table 1. Eighteen
patients (75%) had BRAF wild-type, and 6 (25%) had BRAF
mutant. All 24 patients received nivolumab, however, one
Table 1. Demographics and baseline characteristics of Japanese
patients with previously untreated advanced melanoma given
nivolumab (n = 24)
Characteristic Nivolumab (n = 24)
Sex
Male 14 (58.3)
Female 10 (41.7)
Age, years
<65 13 (54.2)
≥65 11 (45.8)
Median (range), years 63.0 (26–81)
Performance status (ECOG)
0 16 (66.7)
1 8 (33.3)
Stage
IV 3 (12.5)
Recurrent 21 (87.5)
Melanoma type
Lentigo maligna 0 (0.0)
Superficial spreading 6 (25.0)
Nodular 1 (4.2)
Acral lentiginous 7 (29.2)
Other 10 (41.7)
Previous resection
Yes 23 (95.8)
Previous radiation therapy
Yes 3 (12.5)
Number of previous adjuvant therapies
0 9 (37.5)
1 7 (29.2)
≥2 8 (33.3)
BRAF V600 status
Mutation 6 (25.0)
Wild-type 18 (75.0)
Data given as n (%) unless otherwise stated. ECOG, Eastern Coopera-
tive Oncology Group.
Fig. 1. Patient disposition during the study (n = 23).
Table 2. Response and survival of Japanese patients with previously
untreated advanced melanoma given nivolumab (n = 23)
IRC assessed, n
(%)
Investigator assessed, n
(%)
Total patients 23 (100.0) 23 (100.0)
Best overall response
CR 2 (8.7) 0 (0.0)
PR 6 (26.1) 10 (43.5)
SD 7 (30.4) 8 (34.8)
PD 7 (30.4) 5 (21.7)
No lesion found† 1 (4.3) 0 (0.0)
Overall response rate
(CR+PR)
8 (34.8) 10 (43.5)
90% CI, % 20.8, 51.9 28.1, 60.3
Disease control rate
(CR+PR+SD)
15 (65.2) 18 (78.3)
90% CI, % 48.1, 79.2 61.6, 89.0
Duration of response (IRC assessed)
Median, months Not reached –
Range, months 1.4–17.1 –
Progression-free survival
Median, months 5.9 9.8
90% CI, months 2.8, 12.2 2.8, –
Rate at 12 months, % 38.3 42.7
90% CI, % 21.8, 54.6 25.5, 58.9
Rate at 18 months, % 28.7 37.9
90% CI, % 14.3, 44.9 21.5, 54.3
Overall survival
Median, months Not reached
90% CI, months 12.02, –
Rate at 12 months, % 16 (69.6)
90% CI, % 50.8, 82.3
Rate at 18 months, % 13 (56.5)
90% CI, % 38.0, 71.4
†Measurable lesion was found by investigator on site but not by
independent radiology review committee (IRC) throughout the study.
–, Censored value; CI, confidence interval; CR, complete response; PD,
progressive disease; PR, partial response; SD, stable disease.
Fig. 2. Kaplan–Meier analysis of overall survival (OS) in Japanese
patients with previously untreated advanced melanoma given nivolu-
mab (n = 23). Purple, yellow, and black lines represent patients with
BRAF wild-type, patients with BRAF mutation, and total patients,
respectively. CI, confidence interval; NR, not reached.
Cancer Sci | June 2017 | vol. 108 | no. 6 | 1225 © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Yamazaki et al.
patient was excluded from the full analysis set because the
patient met one of the exclusion criteria (double cancer) after
enrollment (Fig. 1). Six patients were receiving treatment at
the cut-off point and continued with further treatment. Of the
remaining 18 patients, 15 were in the follow-up stage at cut-
off, because of PD (nine patients, 37.5%), clinical symptoms
indicating cancer progression (two patients, 8.3%), or the
physician’s decision (four patients, 16.7%). The other three
patients discontinued the study without entering the follow-up
stage because of disease progression. A median of 23 doses
(range, 2–46) of nivolumab were administered, with a median
treatment duration of 11.9 months (range 0.5–21.0). The med-
ian follow-up was 18.8 months (range, 2.0–21.5 months).
Efficacy. The IRC-assessed and investigator-assessed ORRs
are summarized in Table 2. The IRC-assessed ORR was
34.8% (90% CI, 20.8, 51.9) and the investigator-assessed ORR
was 43.5% (90% CI, 28.1, 60.3), indicating similar results for
both assessment methods. The lower limits of the 90% CI in
both IRC-assessed and investigator-assessed ORRs were higher
than the threshold response rate of 6.0% estimated using dacar-
bazine data. The best overall responses assessed by IRC were
CR in two patients (8.7%), PR in six patients (26.1%), and SD
in seven patients (30.4%), giving a disease-control rate
(CR+PR+SD) of 65.2%.
The median OS was not reached, and the proportion of
patients surviving at 18 months was 56.5% (Table 2, Fig. 2).
The median PFS evaluated by IRC was 5.9 months (90% CI,
2.8, 12.2) (Table 2, Fig. 3).
A decrease in target-tumor diameter was observed in more
than half the patients (Fig. 4), and patients who had decreased
tumor diameter also had long antitumor effects (Fig. 5,6).
Response was observed in eight patients and was persistent in
five of eight patients until the cut-off date. The durable
response rate for 12 months, estimated by Kaplan–Meier meth-
ods, was 71.4%.
Safety. Adverse events were reported in 22 patients (91.7%),
including AEs of grade ≥3 in five (20.8%) patients. Treatment-
related AEs were found in 20 patients (83.3%), including three
(12.5%) with treatment-related AEs grade ≥3 (Table 3). No
death occurred during the study period. The most commonly
observed treatment-related AEs were vitiligo (nine patients,
37.5%), pruritus (six patients, 25.0%), hypothyroidism (six
patients, 25.0%), and malaise (six patients, 25.0%). Serious
treatment-related AEs were reported in three patients (12.5%),
including colitis, abnormal hepatic function, renal impairment,
and pleural effusion. Treatment was temporarily interrupted in
two of these patients (colitis and renal impairment). Two
patients (8.3%) discontinued the study because of treatment-
related AEs (colitis and pleural effusion). Treatment-related
select AEs were found in seven patients (29.2%). The only
Fig. 3. Kaplan–Meier analysis of progression-free survival (PFS) in
Japanese patients with previously untreated advanced melanoma
given nivolumab (n = 23), estimated using data evaluated by indepen-
dent radiology review committee. Purple, yellow, and black lines rep-
resent patients with BRAF wild-type, patients with BRAF mutation,
and total patients, respectively. CI, confidence interval; NR, not
reached.
Fig. 4. Maximum change in target-lesion diameter in relation to
BRAF genotype in Japanese patients with previously untreated
advanced melanoma given nivolumab (n = 23). Maximum changes in
target-lesion diameter from baseline evaluated by independent radiol-
ogy review committee. Purple and yellow bars represent patients with
BRAF wild-type and mutation, respectively.
Fig. 5. Change in target-lesion diameter over time
in relation to BRAF genotype in Japanese patients
with previously untreated advanced melanoma
given nivolumab (n = 23). Change in target-lesion
diameter evaluated by independent radiology
review committee. Purple and yellow plots
represent patients with BRAF wild-type and
mutation, respectively.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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treatment-related select AE of grade ≥3 was colitis (4.2%),
which was observed twice in the same patient, who recovered
from the first episode after study-drug withdrawal and treat-
ment with corticosteroids, but had another episode of colitis
146 days later, after which study treatment was discontinued.
The second episode of colitis improved 71 days after its initial
appearance.
BRAF subgroup analyses. Among 23 patients, 17 (73.9%) had
BRAF wild-type and six (26.1%) had BRAF mutation. The
IRC-evaluated ORRs were 23.5% in patients with BRAF wild-
type (90% CI, 11.0, 43.3), and 66.7% in patients with a BRAF
mutation (90% CI, 34.7, 88.3) (Table 4). Regardless of BRAF
genotype, the lower limit of the 90% CI was higher than the
threshold response rate of 6.0% estimated using dacarbazine
data. The OS rates at 18 months were 52.9% and 66.7% in
patients with BRAF wild-type and mutation, respectively
(Table 4, Fig. 2). The median OS was not reached in either
subgroup. The median PFS was 4.2 months in patients with
BRAF wild-type, but was not reached in patients with BRAF
mutation (Table 4, Fig. 3).
Fig. 6. Time to and duration of response in
Japanese patients with previously untreated
advanced melanoma given nivolumab (n = 23), in
relation to BRAF genotype. Time to and duration of
response evaluated by independent radiology
review committee. Purple and yellow bars represent
patients with BRAF wild-type and BRAF mutant,
respectively, on treatment. Arrow, date of censor;
brown bar, patients off treatment; closed circle,
date of first response.
Table 3. Treatment-related adverse events (AEs) in Japanese
patients with previously untreated advanced melanoma given
nivolumab (n = 23)
All grades, n (%) Grade ≥3, n (%)
Overall 20 (83.3) 3 (12.5)
Treatment-related AEs observed in ≥10% of patients
Vitiligo 9 (37.5) 0 (0.0)
Pruritus 6 (25.0) 0 (0.0)
Hypothyroidism 6 (25.0) 0 (0.0)
Malaise 6 (25.0) 0 (0.0)
Weight decreased 3 (12.5) 0 (0.0)
Appetite decreased 3 (12.5) 0 (0.0)
Arthralgia 3 (12.5) 0 (0.0)
Rash maculo-papular 3 (12.5) 0 (0.0)
Treatment-related AEs leading to discontinuation of treatment
Colitis 1 (4.2) 1 (4.2)
Pleural effusion 1 (4.2) 0 (0.0)
Treatment-related serious AEs
Colitis 1 (4.2) 1 (4.2)
Hepatic function abnormal 1 (4.2) 0 (0.0)
Renal impairment 1 (4.2) 1 (4.2)
Pleural effusion 1 (4.2) 0 (0.0)
Treatment-related select AEs
Endocrine disorders 7 (29.2) 0 (0.0)
Infusion reactions 0 (0.0) 0 (0.0)
Gastrointestinal toxicity 2 (8.3) 1 (4.2)
Hepatotoxicity 1 (4.2) 0 (0.0)
Pulmonary toxicity 1 (4.2) 0 (0.0)
Nephrotoxicity 0 (0.0) 0 (0.0)
Skin toxicity 11 (45.8) 0 (0.0)
Table 4. Response and survival in Japanese patients with previously
untreated advanced melanoma given nivolumab, grouped according
to wild-type and mutant BRAF, assessed by independent radiology
review committee (IRC)
BRAF wild-type, n
(%)
BRAF mutation, n
(%)
Total patients 17 (73.9) 6 (26.1)
Best overall response
CR 1 (5.9) 1 (16.7)
PR 3 (17.6) 3 (50.0)
SD 6 (35.3) 1 (16.7)
PD 6 (35.3) 1 (16.7)
No lesion found† 1 (5.9) 0 (0.0)
Overall response rate
(CR+PR)
4 (23.5) 4 (66.7)
90% CI, % 11.0, 43.3 34.7, 88.3
Disease control rate
(CR+PR+SD)
10 (58.8) 5 (83.3)
90% CI, % 39.3, 75.9 49.8, 96.2
Progression-free survival (IRC-assessed)
Median, months 4.21 Not reached
90% CI, months 1.41, 7.16 1.41, –
Rate at 12 months, % 23.5 83.3
90% CI, % 9.3, 41.5 38.8, 96.5
Rate at 18 months, % 17.6 62.5
90% CI, % 5.8, 34.8 21.2, 86.7
Overall survival
Median, months Not reached Not reached
90% CI, months 7.95, – 12.02, –
Rate at 12 months, % 58.8 100.0
90% CI, % 37.0, 75.4 100.0, 100.0
Rate at 18 months, % 52.9 66.7
90% CI, % 31.7, 70.3 27.0, 88.2
†Measurable lesion was found by investigator on site but not by IRC
throughout the study. –, Censored value; CI, confidence interval;CR,
complete response; PD, progressive disease; PR, partial response; SD,
stable disease.
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Treatment-related AEs were reported in 15 (83.3%) and five
(83.3%) patients with BRAF wild-type and mutant, respec-
tively, and the safety profiles were similar in both genotype
subgroups. However, these data were obtained from a small
number of patients and therefore need to be carefully
interpreted.
Other subgroup analyses. A posteriori subgroup analyses
were carried out to identify possible factors associated with
nivolumab efficacy (Table 5). Median OS was not reached
(90% CI, 16.0, –) during the study period in patients with nor-
mal level (≤ULN) of LDH (determined in clinical tests)
(n = 16). Median OS in patients with abnormal level (>ULN)
of LDH (n = 7) was 11.7 months (90% CI, 3.4, –) (hazard
ratio, 0.30; 90% CI, 0.10, 0.85) (Fig. 7a). Seven of eight
responders experienced treatment-related select AEs, and the
median OS was higher in patients with treatment-related select
AEs (n = 13) (not reached; 90% CI, 0.00, –) compared with
patients without treatment-related select AEs (n = 10) (median,
8.3 months; 90% CI, 3.4, 14.3) (hazard ratio, 0.10; 90% CI,
0.03, 0.36) (Fig. 7b). Notably, 66.7% of patients who devel-
oped vitiligo (included vitiligo vulgaris) responded to nivolu-
mab, compared with only 14.3% without vitiligo. The median
OS was not reached in patients with vitiligo (n = 9), but was
11.8 months (90% CI, 7.6, 16.0) in patients without vitiligo
(n = 14) (Fig. 7c). Generally, patients with normal LDH,
treatment-related select AEs, or vitiligo had longer PFS
(Fig. 7d–f).
Table 5. Subgroup analyses of overall response rate (ORR) in
Japanese patients with previously untreated advanced melanoma
given nivolumab (n = 23)
Patients, n
(%)
ORR (IRC-assessed), %
(90% CI)
Serum lactate dehydrogenase
Normal (≤ULN) 6/16 37.5 (20.8, 57.8)
Abnormal (>ULN) 2/7 28.6 (10.0, 59.1)
Treatment-related select adverse events
Present 7/13 53.8 (32.5, 73.9)
Absent 1/10 10.0 (2.3, 34.8)
Vitiligo as a treatment-related adverse event (including vitiligo
vulgaris)
Present 6/9 66.7 (39.8, 85.8)
Absent 2/14 14.3 (4.8, 35.3)
Cl, confidence interval; IRC, independent radiology review committee;
ULN, upper limit of the normal range.
Fig. 7. Overall survival (OS; upper panels) and progression-free survival (PFS; lower panels) estimated by Kaplan–Meier analyses in subgroups of
Japanese patients with previously untreated advanced melanoma given nivolumab (n = 23). OS (a) and PFS (d) in subgroups stratified by lactate
dehydrogenase (LDH) levels at baseline (normal [≤ upper limit of the normal range [ULN], abnormal [>ULN]). Red and blue lines represent
patients with low and high levels of LDH, respectively. OS (b) and PFS (e) in subgroups stratified by treatment-related select adverse events
(TSAEs). Red and blue lines represent patients with and without TSAEs, respectively. OS (c) and PFS (f) in subgroups stratified by vitiligo during
treatment. Red and blue lines represent patients with and without vitiligo, respectively. CI, confidence interval; HR, hazard ratio; NR, not
reached.
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Discussion
Programmed death 1 inhibitors have been tested in clinical
studies and have shown encouraging antitumor activities and
tolerability in a wide range of advanced or refractory cancers,
including renal cell carcinoma,(17,18) non-small-cell
lung cancer,(19–21) Hodgkin’s or non-Hodgkin’s lym-
phoma,(22,23) ovarian cancer,(24) and melanoma.(11–13)
In this study we investigated the efficacy and safety of the
PD-1-blocking mAb nivolumab in Japanese patients with pre-
viously untreated advanced or recurrent melanoma. The effi-
cacy in responding patients was sustainable, with the median
OS not being reached during the course of this study. These
results showed that nivolumab had good efficacy and was clin-
ically more beneficial than standard dacarbazine therapy in
Japanese patients with previously untreated advanced or recur-
rent melanoma.
The safety profile of nivolumab was similar to that observed
in previous large, international, phase III studies.(11,12) All
treatment-related AEs in the present study were considered to
be manageable by early diagnosis and appropriate treatment,
such as with corticosteroids. These results indicated that nivo-
lumab was tolerable in Japanese patients with previously
untreated advanced melanoma.
We also compared the efficacy and safety profiles of nivolu-
mab in patients with and without BRAF mutations. Nivolumab
showed effective anti-\tumor activity regardless of BRAF geno-
type, with apparently better OS and PFS in patients with BRAF
mutant, although the sample sizes were insufficient to draw a
statistically relevant conclusion. Our results were consistent with
previous studies that reported clinical benefits of nivolumab,
regardless of BRAF genotype.(25,26) Melanomas have been
reported to be more aggressive and resistant to chemotherapy in
patients with BRAF mutations,(27–29) and the available therapeu-
tic options have been limited in these patients. Nivolumab may
thus represent a promising option for these patients.
High pretreatment serum LDH has been associated with
shorter survival in patients with metastatic melanoma,(30,31)
and the similar tendency was observed in our study. Neverthe-
less, some patients with high LDH levels showed a response to
nivolumab, suggesting that it might offer an effective therapeu-
tic option in melanoma patients with elevated LDH.
Patients experiencing treatment-related select AEs and viti-
ligo showed a tendency for better survival in nivolumab-trea-
ted patients in the current study. Immune-related AEs have
previously been shown to be characteristic of PD-1 inhibi-
tors,(32,33) and have a reported association with increased sur-
vival.(32) However, it cannot be ruled out that non-responder
patients discontinued nivolumab so early that immune-related
AEs never appeared.(34)
The present study was limited by the small study group and
the lack of a control group. However, several controlled clini-
cal studies have previously been carried out in patients from
the USA and Europe.(11,12) The efficacy and safety profiles of
nivolumab in the current study were similar to those in
previous trials, suggesting that the clinical data from those
controlled clinical studies were likely to be applicable to the
current Japanese study group.
The present study did not address the antitumor activity of
nivolumab in relation to tumor PD-L1 status. Furthermore,
although nivolumab alone showed an ORR >30% in this study,
combination therapy with another checkpoint inhibitor with a
different mechanism of action, such as the cytotoxic T-lym-
phocyte-associated antigen-4 inhibitor ipilimumab, may further
enhance the therapeutic benefit,(6,13) and patients may respond
differently.(11,35)
In conclusion, nivolumab given at a dose of 3 mg/kg once
every 2 weeks is tolerable and shows favorable anticancer
activity in Japanese patients with previously untreated
advanced or recurrent melanoma, irrespective of BRAF muta-
tion status.
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